Hogendoorn Wouter, Lavida Anthi, Hunink M G Myriam, Moll Frans L, Geroulakos George, Muhs Bart E, Sumpio Bauer E
Section of Vascular Surgery, Yale University School of Medicine, New Haven, Conn; Section of Vascular Surgery, University Medical Center, Utrecht, The Netherlands.
Section of Vascular Surgery, Yale University School of Medicine, New Haven, Conn; Department of Vascular Surgery, Imperial College of Science, Technology and Medicine, London, United Kingdom.
J Vasc Surg. 2014 Dec;60(6):1667-76.e1. doi: 10.1016/j.jvs.2014.08.067. Epub 2014 Sep 26.
True splenic artery aneurysms (SAAs) are a rare but potentially fatal pathology. For many years, open repair (OPEN) and conservative management (CONS) were the treatments of choice, but throughout the last decade endovascular repair (EV) has become increasingly used. The purpose of the present study was to perform a systematic review and meta-analysis evaluating the outcomes of the three major treatment modalities (OPEN, EV, and CONS) for the management of SAAs.
A systematic review of all studies describing the outcomes of SAAs treated with OPEN, EV, or CONS was performed using seven large medical databases. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed to ensure a high-quality review. All articles were subject to critical appraisal for relevance, validity, and availability of data regarding characteristics and outcomes. All data were systematically pooled, and meta-analyses were performed on several outcomes, including early and late mortality, complications, and number of reinterventions.
Original data of 1321 patients with true SAAs were identified in 47 articles. OPEN contained 511 patients (38.7%) in 31 articles, followed by 425 patients (32.2%) in CONS in 16 articles and 385 patients (29.1%) in EV in 33 articles. The CONS group had fewer symptomatic patients (9.5% vs 28.7% in OPEN and 28.8% in EV; P < .001) and fewer ruptured aneurysms (0.2% vs 18.4% in OPEN and 8.8% in EV; P < .001), but no significant differences were found in existing comorbidities. CONS patients were usually older and had smaller-sized aneurysms than patients in the OPEN and EV groups. The only identified difference in baseline characteristics between OPEN and EV was the number of ruptured aneurysms (18.4% vs 8.8%; P < .001). OPEN had a higher 30-day mortality than EV (5.1% vs 0.6%; P < .001), whereas minor complications occurred in a larger number of the EV patients. EV required more reinterventions per year (3.2%) compared with OPEN (0.5%) and CONS (1.2%; P < .001). The late mortality rate was higher in patients treated with CONS (4.9% vs 2.1% in OPEN and 1.4% in EV; P = .04).
EV of SAA has better short-term results compared with OPEN, including significantly lower perioperative mortality. OPEN is associated with fewer late complications and fewer reinterventions during follow-up. Patients treated with CONS showed a higher late mortality rate. Ruptured SAAs are predictors of a significantly higher perioperative mortality compared with nonruptured SAAs in the OPEN and EV groups.
真性脾动脉瘤(SAA)是一种罕见但可能致命的病变。多年来,开放修复术(OPEN)和保守治疗(CONS)一直是首选治疗方法,但在过去十年中,血管内修复术(EV)的应用越来越广泛。本研究的目的是进行一项系统评价和荟萃分析,评估三种主要治疗方式(OPEN、EV和CONS)治疗SAA的疗效。
使用七个大型医学数据库对所有描述采用OPEN、EV或CONS治疗SAA疗效的研究进行系统评价。遵循系统评价和荟萃分析的首选报告项目(PRISMA)指南,以确保高质量的评价。对所有文章进行批判性评估,以确定其相关性、有效性以及有关特征和结局的数据可用性。对所有数据进行系统汇总,并对包括早期和晚期死亡率、并发症以及再次干预次数等多个结局进行荟萃分析。
在47篇文章中确定了1321例真性SAA患者的原始数据。31篇文章中的511例患者(38.7%)接受了OPEN治疗,16篇文章中的425例患者(32.2%)接受了CONS治疗,33篇文章中的385例患者(29.1%)接受了EV治疗。CONS组有症状的患者较少(9.5%,而OPEN组为28.7%,EV组为28.8%;P <.001),破裂动脉瘤较少(0.2%,而OPEN组为18.4%,EV组为8.8%;P <.001),但在现有合并症方面未发现显著差异。CONS组患者通常比OPEN组和EV组患者年龄更大,动脉瘤尺寸更小。OPEN组和EV组在基线特征方面唯一确定的差异是破裂动脉瘤的数量(18.4%对8.8%;P <.001)。OPEN组的30天死亡率高于EV组(5.1%对0.6%;P <.001),而EV组患者发生的轻微并发症更多。与OPEN组(0.5%)和CONS组(1.2%)相比,EV组每年需要更多的再次干预(3.2%;P <.001)。CONS治疗的患者晚期死亡率更高(4.9%,而OPEN组为2.1%,EV组为1.4%;P =.04)。
与OPEN相比,SAA的EV治疗具有更好的短期结果,包括围手术期死亡率显著降低。OPEN与较少的晚期并发症以及随访期间较少的再次干预相关。CONS治疗的患者显示出更高的晚期死亡率。与OPEN组和EV组中的未破裂SAA相比,破裂的SAA是围手术期死亡率显著更高的预测因素。